We are live on ! Find out more
GFM

GF Fund Management Portfolio holdings

AUM $5.98B
1-Year Est. Return 80.99%
This Fund
S&P 500
This Quarter Est. Return
+10.72%
1 Year Est. Return
+80.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$5.85B
AUM Growth
+$338M
Cap. Flow
+$79.4M
Cap. Flow %
1.36%
Top 10 Hldgs %
45.51%
Holding
707
New
76
Increased
198
Reduced
354
Closed
64

Top Buys

Rank Stock Value
1
TER icon
Teradyne
TER
+$60.1M
2
TSLA icon
Tesla
TSLA
+$32.1M
3
TSEM icon
Tower Semiconductor
TSEM
+$29.6M
4
GOOG icon
Alphabet (Google) Class C
GOOG
+$29M
5
PDD icon
Pinduoduo
PDD
+$28.1M

Top Sells

Rank Stock Value
1
AVGO icon
Broadcom
AVGO
+$77.7M
2
BE icon
Bloom Energy
BE
+$53.1M
3
HOOD icon
Robinhood
HOOD
+$24.9M
4
SAP icon
SAP
SAP
+$24.1M
5
BIDU icon
Baidu
BIDU
+$21.5M

Sector Composition

Rank Sector Weight
1 Technology 51.21%
2 Communication Services 15.38%
3 Consumer Discretionary 13.01%
4 Healthcare 6.62%
5 Consumer Staples 4.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALVO icon
451
Alvotech
ALVO
$1.21B
$31.6K ﹤0.01%
6,150
-584
-9% -$3.69K
TRVI icon
452
Trevi Therapeutics
TRVI
$2.61B
$31.5K ﹤0.01%
2,519
-101
-4% -$1.17K
FTRE icon
453
Fortrea Holdings
FTRE
$1.8B
$31.3K ﹤0.01%
1,815
-139
-7% -$1.72K
AGIO icon
454
Agios Pharmaceuticals
AGIO
$1.95B
$31.2K ﹤0.01%
1,145
-105
-8% -$3.68K
DRH icon
455
Diamondrock Hospitality Co
DRH
$2.64B
$30.4K ﹤0.01%
3,396
-68
-2% -$579
DEI icon
456
Douglas Emmett
DEI
$2.02B
$30.4K ﹤0.01%
2,764
-14
-0.5% -$175
IMCR icon
457
Immunocore
IMCR
$1.72B
$29.7K ﹤0.01%
857
-5
-0.6% -$177
EYPT icon
458
EyePoint Inc
EYPT
$1.08B
$29.7K ﹤0.01%
1,626
+143
+10% +$2.03K
TSHA icon
459
Taysha Gene Therapies
TSHA
$1.69B
$29.6K ﹤0.01%
5,383
-486
-8% -$2.36K
INVA icon
460
Innoviva
INVA
$1.57B
$29.3K ﹤0.01%
1,467
+111
+8% +$2.17K
QURE icon
461
uniQure
QURE
$2.93B
$29.3K ﹤0.01%
1,223
+43
+4% +$1.66K
ATAI icon
462
AtaiBeckley Inc
ATAI
$2.66B
$29.2K ﹤0.01%
+7,137
New +$33.7K
KOD icon
463
Kodiak Sciences
KOD
$2.66B
$29.1K ﹤0.01%
+1,042
New +$21.3K
PGEN icon
464
Precigen
PGEN
$2.12B
$29.1K ﹤0.01%
6,952
+541
+8% +$2.09K
RLAY icon
465
Relay Therapeutics
RLAY
$4.24B
$28.8K ﹤0.01%
3,406
-303
-8% -$2.16K
UPB
466
Upstream Bio Inc
UPB
$358M
$28.8K ﹤0.01%
+1,061
New +$26.4K
ORKA
467
Oruka Therapeutics
ORKA
$5.9B
$28.8K ﹤0.01%
950
+144
+18% +$4.01K
COLL icon
468
Collegium Pharmaceutical
COLL
$1.17B
$28.7K ﹤0.01%
620
-58
-9% -$2.43K
NVCR icon
469
NovoCure
NVCR
$1.77B
$28.4K ﹤0.01%
2,199
-206
-9% -$2.64K
RAPP
470
Rapport Therapeutics
RAPP
$2.05B
$28.4K ﹤0.01%
935
+146
+19% +$4.04K
GNL icon
471
Global Net Lease
GNL
$1.86B
$28.3K ﹤0.01%
3,295
-82
-2% -$657
ARDX icon
472
Ardelyx
ARDX
$1.25B
$27.8K ﹤0.01%
4,774
-411
-8% -$2.29K
MBX
473
MBX Biosciences
MBX
$3.16B
$27.8K ﹤0.01%
+882
New +$21.4K
TYRA icon
474
Tyra Biosciences
TYRA
$1.97B
$27.6K ﹤0.01%
1,048
-99
-9% -$1.82K
SHO icon
475
Sunstone Hotel Investors
SHO
$2.18B
$26.7K ﹤0.01%
2,990
-191
-6% -$1.75K
17 18
19
20 21

Similar funds

CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
BP
BC Partners New York $5.96B AUM 15.21% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $5.94B AUM 18.44% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
AL
Appaloosa LP Short Hills, New Jersey $5.93B AUM 44.55% 1-Year Est. Return
CGPCS
Capital Group Private Client Services Los Angeles, California $5.93B AUM 27.73% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

GF Fund Management's Q4 2025 Portfolio in Review

As of Q4 2025, GF Fund Management held 707 positions worth $5.85B, up 6.1% from $5.51B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

GF Fund Management's Q4 2025 filing shows 76 new, 198 increased, 354 reduced and 64 closed positions. Its largest new stake was Teradyne: 350,137 shares worth $67.8M. The largest sale was Broadcom, an estimated $77.7M.

By sector, the portfolio is most concentrated in Technology at 51% of assets, up from 49% a quarter earlier, followed by Communication Services and Consumer Discretionary.

  • GF Fund Management's largest Q4 2025 buy was Teradyne: 350,137 shares worth $67.8M.
  • GF Fund Management added most to Tesla in Q4 2025, an estimated $32.1M increase.
  • GF Fund Management's biggest Q4 2025 reduction was Broadcom, cutting an estimated $77.7M.
  • GF Fund Management fully exited Baidu in Q4 2025, selling an estimated $21.5M.
  • GF Fund Management's ten largest holdings make up 46% of its $5.85B portfolio in Q4 2025.
  • GF Fund Management opened 76 new positions and closed 64 in Q4 2025.
  • GF Fund Management's portfolio value rose 6.1% quarter-over-quarter to $5.85B.

Based on GF Fund Management's 13F filing for Q4 2025, filed 27 Jan 2026.